Innovative Collaboration Yields Promising Brain Cancer Insights
Cordance Medical, a trailblazer in non-invasive medical technologies aimed at treating brain diseases, has joined forces with EXACT Therapeutics (Euronext Growth: EXTX) to share early data that shows remarkable potential in the treatment of brain cancer. Their groundbreaking research indicates a staggering increase of more than 127% to 145% in the uptake of a radiopharmaceutical within brain tumors in mice injected with glioblastoma cells, notorious for being one of the most aggressive and challenging brain cancers to treat.
Mechanisms Behind the Breakthrough Research
The profound results can be attributed to the innovative combination of Exact Therapeutics’ proprietary Acoustic Cluster Therapy (ACT®) and a sophisticated device engineered by Cordance Medical, which delivers ultrasound energy efficiently and non-invasively into the brain. This collaborative study was conducted at The Arctic University of Norway and University Hospital North-Norway under the expert guidance of Dr. Mathias Kranz.
Broader Applications of the Technology
This unique combination of ACT® and the advanced delivery device has extensive potential applications across various brain diseases, potentially enabling access to broader regions of the brain. By utilizing this method, therapeutic agents can be better absorbed, and the blood-brain barrier may be temporarily made more permeable in the targeted areas. Such capabilities mean that this technology could play a crucial role in both diagnostic procedures and focused therapeutic interventions for brain conditions.
Future Research and Development Plans
Currently, further investigations are underway to deepen the understanding of these initial findings. The researchers plan to compile and submit their results for publication in peer-reviewed scientific journals, contributing valuable insights to the field of oncology. The advancement of these studies is critical as it could lead to effective new treatment modalities that can significantly impact patient care.
Comments from Leadership
Dr. Bhaskar Ramamurthy, Co-founder and CEO of Cordance Medical, expressed enthusiasm over this collaborative endeavor, stating, "The combination of the Cordance technology and the ACT® microcluster technology from Exact Therapeutics provides exciting possibilities for accessing and opening larger volumes in the brain without necessarily increasing the focused ultrasound procedure time or the total amount of ultrasound energy." This statement highlights the efficiency and potential of the partnership in transforming treatment approaches.
Importance of the Ongoing Clinical Trials
Dr. Per Walday, CEO of Exact Therapeutics, emphasized the significance of these findings, noting, "These positive results in glioblastoma provide additional early evidence of the versatility of the noninvasive ACT® microcluster technology in cancer therapy. Oncology remains our primary focus, led by our ongoing Phase 2 trial in locally advanced pancreatic cancer, which received IND clearance recently." This dedication to research and development showcases their commitment to improving cancer therapeutics and patient outcomes.
About Cordance Medical
Cordance Medical is dedicated to developing innovative, non-invasive solutions tailored for treating brain diseases. Their flagship NeuroAccess™ platform is specifically designed to enable precise and targeted treatment alternatives, aiming to enhance outcomes for patients worldwide.
About EXACT Therapeutics
On the other hand, EXACT Therapeutics specializes in clinical-stage precision medicine, applying the power of ultrasound and microbubbles to offer targeted drug delivery for cancer therapies. Their Acoustic Cluster Therapy (ACT®) represents a cutting-edge methodology that can be adapted for numerous therapeutic agents, particularly within oncology and other medical areas, including brain diseases.
Frequently Asked Questions
What is the focus of the collaboration between Cordance Medical and EXACT Therapeutics?
The collaboration focuses on developing non-invasive treatments for brain cancer using innovative technologies like Acoustic Cluster Therapy and ultrasound delivery systems.
What results have been observed in the studies involving glioblastoma?
Initial results indicate a significant increase in the uptake of a radiopharmaceutical in brain tumors of glioblastoma-inoculated mice, ranging from 127% to 145%.
How does Acoustic Cluster Therapy (ACT®) work?
ACT® utilizes ultrasound and microbubbles to enhance drug delivery to targeted areas in the brain, potentially increasing efficacy and reducing side effects.
What are the future plans following these findings?
Further studies will be conducted to expand upon these findings, with results expected to be submitted for publication in scientific journals.
Why is the research on glioblastoma particularly important?
Glioblastoma is one of the most aggressive brain cancers, and developing effective treatments is crucial for improving survival rates and patient well-being.
